Information de reference pour ce titreAccession Number: | 00001432-201312000-00006.
|
Author: | Trubiano, Jason a; Phillips, Elizabeth b,c
|
Institution: | (a)Department of Infectious Diseases, Peter MacCallum Cancer Centre, East Melbourne, Victoria (b)The Institute for Immunology & Infectious Diseases, Murdoch University, Murdoch, Western Australia, Australia (c)Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
|
Title: | |
Source: | Current Opinion in Infectious Diseases. 26(6):526-537, December 2013.
|
Abstract: | Purpose of review: The continued emergence of multiresistant pathogens and widespread antimicrobial use has led to a greater emphasis on antimicrobial stewardship programs. Concurrently, an increased awareness of the rising number of antibiotic allergy labels and impact on antimicrobial use has surfaced. The integration of antibiotic allergy de-labeling and antimicrobial stewardship programs may be a pathway worthy of further focus and investigation.
Recent findings: Recent literature has evaluated the efficacy of antibiotic allergy management (historical de-labeling, in-vitro testing, skin prick testing, intradermal testing, and oral challenges) and impact of antibiotic allergy labels on patient outcome. The importance of true and perceived antibiotic allergy cross-reactivity in the setting of [beta]-lactam allergies has been highlighted. The impact of dedicated antibiotic allergy de-labeling clinics, inpatient antibiotic allergy testing, and integrated antimicrobial stewardship programs has been recently appraised.
Summary: More recent literature supports that appropriate antibiotic allergy in-vitro and in-vivo testing and subsequent antibiotic allergy de-labeling, particularly in regard to [beta]-lactams, can decrease broad-spectrum antibiotic use, costs, patient length of stay, and mortality. Integration of antibiotic allergy management into the decision support systems of inpatient and outpatient antimicrobial stewardship programs represents an important opportunity to further improve measured outcomes from antibiotic utilization.
(C) 2013 Lippincott Williams & Wilkins, Inc.
|
Author Keywords: | antibiotic allergy; antimicrobial stewardship; [beta]-lactam; de-labeling.
|
References: | 1[black small square][black small square]. Lagace-Wiens P, Rubinstein E. Adverse reactions to beta-lactam antimicrobials. Expert Opin Drug Saf 2012; 11:381-399.
2. Torres MJ, Blanca M. The complex clinical picture of beta-lactam hypersensitivity: penicillins, cephalosporins, monobactams, carbapenems, and clavams. Med Clin North Am 2010; 94:805-820.
3. Blanca M, Romano A, Torres MJ, et al. Update on the evaluation of hypersensitivity reactions to beta lactams. Allergy 2009; 64:183-193.
4. Charneski L, Deshpande G, Smith SW. Impact of an antimicrobial allergy label in the medical record on clinical outcomes in hospitalized patients. Pharmacotherapy 2011; 31:742-747.
5[black small square]. Sastre J, Manso L, Sanchez-Garcia S, Fernandez-Nieto M. Medical and economic impact of misdiagnosis of drug hypersensitivity in hospitalized patients. J Allergy Clin Immunol 2012; 129:566-567.
6[black small square][black small square]. Caimmi S, Sanfiorenzo C, Caimmi D, et al. Comprehensive allergy work-up is mandatory in cystic fibrosis patients who report a history suggestive of drug allergy to beta-lactam antibiotics. Clin Transl Allergy 2012; 2:10.
7[black small square][black small square]. Rimawi RH, Cook PP, Gooch M, et al. The impact of penicillin skin testing on clinical practice and antimicrobial stewardship. J Hosp Med 2013; 8:341-345.
8. Gell PGH, Coombs RRA. Gell PGH, Coombs RRA. The classification of allergic reactions underlying disease. Clinical aspects of immunology Blackwell Scientific, 2nd ed.Oxford:1963.
9. Pichler WJ. Pichler WJ. Drug hypersensitivity reactions: classification and relationship to T-cell activation. Drug Hypersensitivity. Basel:S Karger Pub; 2007. 168-189.
10[black small square][black small square]. Rive CM, Bourke J, Phillips EJ. Testing for drug hypersensitivity syndromes. Clin Biochem Rev 2013; 34:15-38.
11[black small square][black small square]. Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 2012; 13:1285-1306.
12. Uzzaman A, Cho SH. Chapter 28: classification of hypersensitivity reactions. Allergy Asthma Proc 2012; 33 (Suppl 1):S96-S99.
13. Bircher AJ, Scherer HofmeierF K. Drug hypersensitivity reactions: inconsistency in the use of the classification of immediate and nonimmediate reactions. J Allergy Clin Immunol 2012; 129:263-264.author reply 5-6.
14. Park MA, Li JT. Diagnosis and management of penicillin allergy. Mayo Clin Proc 2005; 80:405-410.
15. Anne S, Reisman RE. Risk of administering cephalosporin antibiotics to patients with histories of penicillin allergy. Ann Allergy Asthma Immunol 1995; 74:167-170.
16. Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology; American College of Allergy, Asthma and Immunology; Joint Council of Allergy, Asthma and ImmunologyDrug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010; 105:259-273.
17. Petz LD. Immunologic cross-reactivity between penicillins and cephalosporins: a review. J Infect Dis 1978; 137 (Suppl):S74-S79.
18. Antunez C, Blanca-Lopez N, Torres MJ, et al. Immediate allergic reactions to cephalosporins: evaluation of cross-reactivity with a panel of penicillins and cephalosporins. J Allergy Clin Immunol 2006; 117:404-410.
19[black small square][black small square]. Unger NR, Gauthier TP, Cheung LW. Penicillin skin testing: potential implications for antimicrobial stewardship. Pharmacotherapy 2013; 33:856-867.
20. Romano A, Gaeta F, Valluzzi RL, et al. IgE-mediated hypersensitivity to cephalosporins: cross-reactivity and tolerability of penicillins, monobactams, and carbapenems. J Allergy Clin Immunol 2010; 126:994-999.
21[black small square][black small square]. Bourke J, Hollingsworth PR, McLean-Tooke P, et al. Penicillin de-labelling in tertiary care clinics: safe and efficacious but incomplete effectiveness. Int Med J 2012; 42 (Supplement 4):21-22.
22. Pipet A, Veyrac G, Wessel F, et al. A statement on cefazolin immediate hypersensitivity: data from a large database, and focus on the cross-reactivities. Clin Exp Allergy 2011; 41:1602-1608.
23. Patriarca G, Schiavino D, Lombardo C, et al. Tolerability of aztreonam in patients with IgE-mediated hypersensitivity to beta-lactams. Int J Immunopathol Pharmacol 2008; 21:375-379.
24. Buonomo A, Nucera E, De Pasquale T, et al. Tolerability of aztreonam in patients with cell-mediated allergy to beta-lactams. Int Arch Allergy Immunol 2011; 155:155-159.
25. Burke P, Burne SR. Allergy associated with ciprofloxacin. BMJ 2000; 320:679.
26. Gonzalez I, Lobera T, Blasco A, del Pozo MD. Immediate hypersensitivity to quinolones: moxifloxacin cross-reactivity. J Investig Allergol Clin Immunol 2005; 15:146-149.
27. Schmid DA, Depta JP, Pichler WJ. T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. Clin Exp Allergy 2006; 36:59-69.
28. Chang B, Knowles SR, Weber E. Immediate hypersensitivity to moxifloxacin with tolerance to ciprofloxacin: report of three cases and review of the literature. Ann Pharmacother 2010; 44:740-745.
29. Mori K, Maru C, Takasuna K. Characterization of histamine release induced by fluoroquinolone antibacterial agents in-vivo and in-vitro. J Pharm Pharmacol 2000; 52:577-584.
30[black small square]. Bosse D, Lemire C, Ruel J, et al. Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection. Infection 2013; 41:579-582.
31. Schulze S, Wollina U. Gentamicin-induced anaphylaxis. Allergy 2003; 58:88-89.
32. Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev 1996; 15:9-50.
33. Yee D, Valiquette C, Pelletier M, et al. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med 2003; 167:1472-1477.
34. Sood A, Taylor JS. Bacitracin: allergen of the year. Am J Contact Dermat 2003; 14:3-4.
35. Agrawal S, Agarwalla A. Dapsone hypersensitivity syndrome: a clinico-epidemiological review. J Dermatol 2005; 32:883-889.
36. Notman MJ, Phillips EJ, Knowles SR, et al. Clindamycin skin testing has limited diagnostic potential. Contact Dermatitis 2005; 53:335-338.
37. Kraft D, Roth A, Mischer P, et al. Specific and total serum IgE measurements in the diagnosis of penicillin allergy. A long term follow-up study. Clin Allergy 1977; 7:21-28.
38[black small square][black small square]. Johansson SG, Adedoyin J, van Hage M, et al. False-positive penicillin immunoassay: an unnoticed common problem. J Allergy Clin Immunol 2013; 132:235-237.
39. Leysen J, Sabato V, Verweij MM, et al. The basophil activation test in the diagnosis of immediate drug hypersensitivity. Expert Rev Clin Immunol 2011; 7:349-355.
40. Macy E, Richter PK, Falkoff R, Zeiger R. Skin testing with penicilloate and penilloate prepared by an improved method: amoxicillin oral challenge in patients with negative skin test responses to penicillin reagents. J Allergy Clin Immunol 1997; 100:586-591.
41. Torres MJ, Ariza A, Fernandez J, et al. Role of minor determinants of amoxicillin in the diagnosis of immediate allergic reactions to amoxicillin. Allergy 2010; 65:590-596.
42. Kranke B, Aberer W. Skin testing for IgE-mediated drug allergy. Immunol Allergy Clin North Am 2009; 29:503-516.
43. Romano A, Torres MJ, Fernandez J, et al. Allergic reactions to ampicillin. Studies on the specificity and selectivity in subjects with immediate reactions. Clin Exp Allergy 1997; 27:1425-1431.
44. Romano A, Bousquet-Rouanet L, Viola M, et al. Benzylpenicillin skin testing is still important in diagnosing immediate hypersensitivity reactions to penicillins. Allergy 2009; 64:249-253.
45. Lin E, Saxon A, Riedl M. Penicillin allergy: value of including amoxicillin as a determinant in penicillin skin testing. Int Arch Allergy Immunol 2010; 152:313-318.
46. Torres MJ, Ariza A, Mayorga C, et al. Clavulanic acid can be the component in amoxicillin-clavulanic acid responsible for immediate hypersensitivity reactions. J Allergy Clin Immunol 2010; 125:502-505.e2.
47[black small square]. Prematta T, Shah S, Ishmael FT. Physician approaches to beta-lactam use in patients with penicillin hypersensitivity. Allergy Asthma Proc 2012; 33:145-151.
48. Fernandez T, Torres MJ, R-Pena R, et al. Decrease of selective immunoglobulin E response to amoxicillin despite repeated administration of benzylpenicillin and penicillin V. Clin Exp Allergy 2005; 35:1645-1650.
49. Sullivan TJ, Wedner HJ, Shatz GS, et al. Skin testing to detect penicillin allergy. J Allergy Clin Immunol 1981; 68:171-180.
50. Solensky R, Earl HS, Gruchalla RS. Lack of penicillin resensitization in patients with a history of penicillin allergy after receiving repeated penicillin courses. Arch Intern Med 2002; 162:822-826.
51. Bittner A, Greenberger PA. Incidence of resensitization after tolerating penicillin treatment in penicillin-allergic patients. Allergy Asthma Proc 2004; 25:161-164.
52. Travassos AR, Pacheco D, Antunes J, et al. The importance of patch tests in the differential diagnosis of adverse drug reactions. An Bras Dermatol 2011; 86 (4 Suppl 1):S21-S23.
53. Phillips EJ, Sullivan JR, Knowles SR, Shear NH. Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir. AIDS 2002; 16:2223-2225.
54. Schiavino D, Nucera E, Lombardo C, et al. Cross-reactivity and tolerability of imipenem in patients with delayed-type, cell-mediated hypersensitivity to beta-lactams. Allergy 2009; 64:1644-1648.
55. Gonzalo-Garijo MA, Rodriguez-Nevado I, de Argila D. Patch tests for diagnosis of delayed hypersensitivity to cephalosporins. Allergol Immunopathol (Madr) 2006; 34:39-41.
56. Pereira N, Canelas MM, Santiago F, et al. Value of patch tests in clindamycin-related drug eruptions. Contact Dermatitis 2011; 65:202-207.
57. Perrin-Lamarre A, Petitpain N, Trechot P, et al. Glycopeptide-induced cutaneous adverse reaction: results of an immunoallergic investigation in eight patients. Ann Dermatol Venereol 2010; 137:101-105.
58. Torres MJ, Mayorga C, Blanca M. Nonimmediate allergic reactions induced by drugs: pathogenesis and diagnostic tests. J Investig Allergol Clin Immunol 2009; 19:80-90.
59. Kano Y, Hirahara K, Mitsuyama Y, et al. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy 2007; 62:1439-1444.
60. Nagao-Dias AT, Teixeira FM, Coelho HL. Diagnosing immune-mediated reactions to drugs. Allergol Immunopathol (Madr) 2009; 37:98-104.
61. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358:568-579.
62. Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141:338-347.
63. O'Donohue J, Oien KA, Donaldson P, et al. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000; 47:717-720.
64. Donaldson PT, Daly AK, Henderson J, et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010; 53:1049-1053.
65[black small square]. Carr DF, Chaponda M, Jorgensen AL, et al. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population. Clin Infect Dis 2013; 56:1330-1339.
66[black small square]. Phillips E, Bartlett JA, Sanne I, et al. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr 2013; 62:e55-e57.
67. Yuan J, Guo S, Hall D, et al. Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 2011; 25:1271-1280.
68. Likanonsakul S, Rattanatham T, Feangvad S, et al. HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients. AIDS Res Ther 2009; 6:22.
69. Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients. Pharmacogenet Genomics 2009; 19:139-146.
70. Vitezica ZG, Milpied B, Lonjou C, et al. HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008; 22:540-541.
71. Littera R, Carcassi C, Masala A, et al. HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients. AIDS 2006; 20:1621-1626.
72. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19:97-99.
73[black small square]. Garcia Nunez I, BarasonaVillarejo MJ, et al. Diagnosis of patients with immediate hypersensitivity to beta-lactams using retest. J Investig Allergol Clin Immunol 2012; 22:41-47.
74[black small square]. Sagar PS, Katelaris CH. Utility of penicillin allergy testing in patients presenting with a history of penicillin allergy. Asia Pac Allergy 2013; 3:115-119.
75. Macy E. The clinical evaluation of penicillin allergy: what is necessary, sufficient and safe given the materials currently available? Clin Exp Allergy 2011; 41:1498-1501.
76. Rerkpattanapipat T, Chiriac AM, Demoly P. Drug provocation tests in hypersensitivity drug reactions. Curr Opin Allergy Clin Immunol 2011; 11:299-304.
77. Padial A, Antunez C, Blanca-Lopez N, et al. Nonimmediate reactions to beta-lactams: diagnostic value of skin testing and drug provocation test. Clin Exp Allergy 2008; 38:822-828.
78. Borch JE, Bindslev-Jensen C. Full-course drug challenge test in the diagnosis of delayed allergic reactions to penicillin. Int Arch Allergy Immunol 2011; 155:271-274.
79[black small square][black small square]. Hjortlund J, Mortz CG, Skov PS, et al. One-week oral challenge with penicillin in diagnosis of penicillin allergy. Acta Derm Venereol 2012; 92:307-312.
80. Richter AG, Wong G, Goddard S, et al. Retrospective case series analysis of penicillin allergy testing in a UK specialist regional allergy clinic. J Clin Pathol 2011; 64:1014-1018.
81[black small square]. Picard M, Paradis L, Nguyen M, et al. Outpatient penicillin use after negative skin testing and drug challenge in a pediatric population. Allergy Asthma Proc 2012; 33:160-164.
82. Warrington RJ, Burton R, Tsai E. The value of routine penicillin allergy skin testing in an outpatient population. Allergy Asthma Proc 2003; 24:199-202.
83. National Patient Safety Agency (2007). Safety in doses: medication safety incidents in the NHS. http://www.nrls.npsa.nhs.uk/Easy...- ouverture dans une nouvelle fenêtre. [Accessed 1 April 2013]
84. Arroliga ME, Radojicic C, Gordon SM, et al. A prospective observational study of the effect of penicillin skin testing on antibiotic use in the intensive care unit. Infect Control Hosp Epidemiol 2003; 24:347-350.
85. del Real GA, Rose ME, Ramirez-Atamoros MT, et al. Penicillin skin testing in patients with a history of beta-lactam allergy. Ann Allergy Asthma Immunol 2007; 98:355-359.
86. MacLaughlin EJ, Saseen JJ, Malone DC. Costs of beta-lactam allergies: selection and costs of antibiotics for patients with a reported beta-lactam allergy. Arch Fam Med 2000; 9:722-726.
87. Lee CE, Zembower TR, Fotis MA, et al. The incidence of antimicrobial allergies in hospitalized patients: implications regarding prescribing patterns and emerging bacterial resistance. Arch Intern Med 2000; 160:2819-2822.
88. Park M, Markus P, Matesic D, Li JT. Safety and effectiveness of a preoperative allergy clinic in decreasing vancomycin use in patients with a history of penicillin allergy. Ann Allergy Asthma Immunol 2006; 97:681-687.
89. Park MA, McClimon BJ, Ferguson B, et al. Collaboration between allergists and pharmacists increases beta-lactam antibiotic prescriptions in patients with a history of penicillin allergy. Int Arch Allergy Immunol 2011; 154:57-62.
|
Language: | English.
|
Document Type: | ANTIMICROBIAL AGENTS: Edited by Monica A. Slavin and Deenan Pillay.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0951-7375
|
NLM Journal Code: | 8809878
|
DOI Number: | https://dx.doi.org/10.1097/QCO.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|